Dose Escalation Followed by Study of RAD001 in Combination With Trastuzumab in HER2-Positive Metastatic Breast Cancer
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Breast Cancer
Interventions: DRUG: Everolimus|DRUG: Trastuzumab
Sponsor: Beth Israel Deaconess Medical Center
Collaborators: Novartis Pharmaceuticals|Dana-Farber Cancer Institute